Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

NewsGuard 100/100 Score

Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK.

Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination Study with Allopurinol

Results presented from the ongoing blinded extension portion of Ardea's Phase 2b study (study 203) of lesinurad in patients who did not achieve target on allopurinol therapy alone demonstrated that for those patients who have reached week 28 of the extension period, 91 percent of those patients receiving lesinurad in combination with allopurinol achieved serum urate (sUA) levels below the clinically important target of 6 mg/dL.  Importantly, continued reductions in sUA were observed beyond the initial 28 days of dosing with a majority of the responding patients remaining on a 200 mg dose of lesinurad thus far in the extension period.  These preliminary results are from the extension portion of a 28-day, randomized, double-blind, placebo-controlled Phase 2b study evaluating lesinurad in combination with allopurinol in 208 gout patients with elevated sUA greater than or equal to 6 mg/dL who were not adequately responding despite being on a stable dose of allopurinol.  Following the 28-day primary dosing period and at least a two-week washout, 126 patients entered the optional extension period and restarted dosing with 200 mg of lesinurad or placebo.  Non-responding patients can be escalated up to 400 mg or 600 mg of lesinurad, at the investigators' discretion.  Currently, 30 patients have been dosed for at least 6 months.

Final results were also presented from the completed 28-day main portion of study 203. At the highest lesinurad dose tested in this study, patients achieved a 30 percent mean reduction in sUA levels after 4 weeks, compared to a 3 percent mean increase on allopurinol plus placebo (p< 0.0001).  This resulted in a response rate of 79 percent for the 600 mg dose (p< 0.0001) using the more rigorous "intent-to-treat" (ITT) analysis and 87 percent using a "last observation carried forward" (LOCF) analysis. As a result, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.

The combination of lesinurad and allopurinol was generally well tolerated in the main 28-day dosing period and has been well tolerated in the ongoing extension period. Adverse events were infrequent, not dose related and comparable between the groups receiving lesinurad and placebo.

Preclinical Data Presented

The Company also presented data from a completed preclinical study evaluating lesinurad's effect on the hyperuricemia caused by the commonly used diuretic, hydrochlorothiazide. Hypertension is prevalent in gout patients and they are often treated with anti-hypertensive agents such as thiazide diuretics.  These agents have for some time been known to reduce uric acid excretion from the kidney, and thus increase sUA levels, which can exacerbate the condition of gout patients. The reduction in uric acid excretion by these agents is believed to be due to activation of a uric acid transporter in the kidney known as OAT4.  Results from a completed preclinical study were presented at EULAR showing that lesinurad is an active inhibitor of the OAT4 transporter. This secondary activity may significantly offset the sUA-increasing effects of thiazide diuretics, thereby achieving a secondary benefit for gout patients taking this common treatment for hypertension.  Consistent with these preclinical results, a high level of response was observed with lesinurad in the subset of patients receiving thiazide diuretics in study 203.

Results Presented from Phase 1b Study Evaluating the Combination of Lesinurad and Febuxostat

Final results were also presented from a completed Phase 1b study evaluating the combination of lesinurad and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini) in gout patients with sUA of at least 8 mg/dL.

In this Phase 1b clinical study evaluating the use of lesinurad in combination with febuxostat in 21 gout patients, 100 percent of patients receiving the combination achieved sUA levels below 6 mg/dL, compared to 67 percent and 56 percent for patients receiving 40 mg and 80 mg, respectively, of febuxostat alone. With the highest dose of febuxostat combined with either 400 mg or 600 mg lesinurad, 100 percent of patients reached sUA levels below 4 mg/dL.  No patient achieved these reduced sUA levels on this dose of febuxostat alone. The combination of lesinurad and febuxostat was well tolerated with no serious adverse events or discontinuations due to adverse events.

"While the 28-day results from our 203 Study were encouraging, the high rate of sustained uric acid lowering achieved during the extension period, using the lower doses of lesinurad, are even more impressive," said Barry D. Quart, PharmD, President and Chief Executive Officer of Ardea Biosciences. "Continued dosing with 200 mg produced results similar to those seen at 28 days with higher doses, giving us a wide range of doses to consider for the Phase 3 program."

Source: http://www.ardeabio.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows healthy plant-based diets lower gout risk, unhealthy diets raise it